http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0663826-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a722744e77c81c5f5cf415087e2ee92b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-715 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-401 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-405 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-198 |
| filingDate | 1992-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18b9affb5a4ea96b9b0d57557ad1b91d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d709dac36a86c032a2cc7834c81b9f2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9b73ad6f46c3b18722ea6c064e6ef77 |
| publicationDate | 1995-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0663826-A1 |
| titleOfInvention | Amino acids containing parenteral formulations for the treatment of hypotension and related pathologies |
| abstract | An anti-hypotensive formulation comprising an essentially arginine-free or low arginine (less than about 0.1 %, most preferably, about 0.01 %) containing mixture of amino acids is provided. The formulations may further include ornithine, citrulline or both. Combination regimens of the described TPN solutions and an arginine analog, or the TPN formations with an anti-endotoxine antibody, an interleukin-1 receptor antagonist, or an anti-tumor necrosis antibody are also provided. Methods for prophylaxis and treatment of systemic hypotension in employing these combination regimens are also provided. A method for treating hypotension caused by nitric oxide synthesis, through administering a low or essentially arginine-free parenteral formulation is described. Methods for treating an animal in septic shock are also disclosed. Prophylaxis or treatment of systemic hypotension, particularly that hypotension incident to chemotherapeutic treatment with biologic response modifiers, such as tumor necrosis factor or interleukin-1 or -2, may be accomplished through the administration of the defined anti-hypotensive formulations or combination regimens with a TPN formulation until physiologically acceptable systolic blood pressure levels are achieved in the animal. Treatment of an animal for septic shock induced by endotoxin may also be accomplished by administering to the animal the arginine-free formulations described. Methods for providing nutritional support for an animal at risk of or in septic shock may also be provided through the administration of an arginine-free formulation or the combination regimens. |
| priorityDate | 1991-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 577.